NDAORALTABLET
Approved
Sep 2010
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEYAZ is an oral contraceptive combining drospirenone and ethinyl estradiol with added levomefolate calcium (a reduced form of folic acid). It prevents pregnancy through hormonal suppression and provides folate supplementation to reduce risk of neural tube defects in case of contraceptive failure or unplanned pregnancy. The product targets women of reproductive age seeking combined hormonal contraception with integrated micronutrient support.
$0.032MPart D
Peak4.2 years to LOEProduct is in peak commercial phase with modest Part D utilization; team focus likely on market maintenance and retention strategies as LOE approaches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on BEYAZ at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.